Evaluation of Tumor Heterogeneity in Prostate Biopsy Samples

Pavithra D. Arachchige(Henry Ford Health System), Nallasivam Palanisamy(Henry Ford Health System), Mireya Diaz‐Insua, Gaury Dhamdhere(Henry Ford Health System), Madhu P. Menon, James O. Peabody(Henry Ford Hospital), Nilesh Gupta(Henry Ford Health System), Sean R. Williamson(Cleveland Clinic), Shannon Carskadon(Henry Ford Health System), Ryan Craig
Unknown
January 1, 2019
Cited by 0

Related Papers

The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma
|The American Journal of Surgical Pathology|2020|705
Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth
|JAMA|2015|420
Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma
|Clinical Cancer Research|2013|358
New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia
|Modern Pathology|2021|254
Succinate dehydrogenase-deficient renal cell carcinoma: detailed characterization of 11 tumors defining a unique subtype of renal cell carcinoma
|Modern Pathology|2014|227